Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. - Wikidata - awgldk - TriplyDB

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

http://www.wikidata.org/entity/Q38887681

about

Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer Drug Resistance to EGFR Inhibitors in Lung Cancer Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.The pharmacogenomics of drug resistance to protein kinase inhibitors.Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma.Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy.Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.Extinction rates in tumour public goods games A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR.The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.Understanding and targeting resistance mechanisms in NSCLC.Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.

P2860

Q26739777-A37E6DB2-8F42-4F35-91A7-4E4F48514743 Q26741318-D8DA845B-01C4-4541-A2E5-47C8E1B2EFFB Q26748851-F3A0686B-6F5E-4B35-95D5-068CEBF51894 Q28069708-89C0CC0D-DC9B-4450-AFB8-83AD3D6E31FB Q33618558-1B5A5710-53A0-474D-8AFF-9595536C1D9A Q33740707-10CE63E2-63EC-496F-AAB0-1EE69A657607 Q34497467-84F3884D-8A27-4662-B0F6-A40A31F99228 Q34550460-74A57BB8-EAF3-4AD4-B1FA-AEE7D586CCC3 Q35844624-BBC21D2B-A20C-4E66-B797-046095017B3C Q36427381-CF638F0E-C8C0-4F85-8EA7-DA9786C306CF Q36605057-D24539F4-3ECA-4A07-A7EB-D3C57572AF20 Q36775204-4CC573B2-8706-4D9F-863B-A65FCD115A37 Q36801144-D4F3084B-1796-494C-B375-E542606F45A5 Q36834883-5928938E-144B-4E2B-A062-25B20516A2B3 Q36989342-C29ECD7D-62B4-41A0-9B01-55E252FB3E42 Q37000646-201C0A30-5DDE-4FEE-BD1A-26C0E1A9FCAD Q37085219-37575EEB-9AE7-4E17-8984-D0C0FE2F6512 Q37412555-A5958A1E-68BB-468C-8872-656734AAF767 Q37726138-ED5A41A6-E67B-4A88-A346-DD579E396B83 Q38598893-D9AB13BC-9A40-4A28-B9E4-250369026033 Q38731759-F356D615-8CD9-450E-9186-7CAE735C22BD Q38740315-AC43F6E9-563C-402E-9038-8D1FCE9CC41B Q38745430-76F5517E-FA95-4BAB-B6E0-785EC30D5E3E Q38790929-74EF7131-7AF6-46E0-B24C-9A4A0E372A16 Q38833666-B6462F82-7858-46AE-B226-340A1CBCE5BB Q38952751-D7697352-E3EA-4D92-A3D6-A4C76C3D57BA Q38991958-154802B1-B398-480D-B831-59070E9F1438 Q39023478-DC765B84-B050-44FD-B5FD-F82FC78A2622 Q39114552-B5D5055E-6493-4B86-AC76-DCFE628E922C Q39176363-2114F588-2F25-4997-A9BA-0B681555D846 Q39255218-2EFA5153-E0CE-4018-9D25-C9A34B563C8B Q39288360-D2F89B6E-F095-402E-8670-90D1BF975156 Q41911703-5DB8F974-9C52-42A5-A4F8-EDAB81599981 Q42262863-E1D181F9-95C6-4A66-990E-5817EA78859F Q42367902-C4505FE3-E3A6-498B-9C28-BD4ACFC06856 Q42378470-240ECC6B-9F7F-4FA7-9CE8-71F5AFE4B3E7 Q45983599-456D6141-112C-4F54-9C5B-B068B00DB9FF Q46915997-2D1B4F97-9C5C-4FAB-83A1-3819B38E034A Q47095218-2041ADD1-673B-4EB2-A605-20858B2D6BC6 Q47146662-C425128A-F68A-4641-A9B1-73F2F6968010

P2860

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

http://www.wikidata.org/entity/Q38887681

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Acquired Resistance to the Mut ...... gnaling in Preclinical Models.

@en

type

label

Acquired Resistance to the Mut ...... gnaling in Preclinical Models.

@en

prefLabel

Acquired Resistance to the Mut ...... gnaling in Preclinical Models.

@en

P1433

Q38887681-B0287AB8-59A3-48BF-963C-882AA69FBE82

P1476

Q38887681-57ECFA6F-E201-4D5A-816B-8D14DF7486B8

P2093

Q38887681-007CC33F-63B0-4B85-8099-4B4D5309BE18

Q38887681-16052C58-228C-4540-A47B-1890304C8B9E

Q38887681-211F6C3C-0523-46E7-91E8-EEA6CFF8A56D

Q38887681-276DDC76-7AD7-454F-B0B4-DFA3FCFF2984

Q38887681-385FF1EA-21E9-4930-84B9-09228E260A9C

Q38887681-50E5D746-4729-4880-BE31-B96FA91D88DB

Q38887681-56562011-A55A-4316-B347-EFFCA7F0A607

Q38887681-691DBF63-2279-4A22-927C-533B31BE453B

Q38887681-69998ED0-8B60-4F63-8B4F-59D3B029E6EC

Q38887681-6B2455E6-6284-4C36-848B-2EC35EE9E2C9

P2860

Q38887681-00740C30-90F9-4948-9A89-639BA15C3D2B

Q38887681-0B141BB6-EC6E-4E9F-AB20-24B699CA52FF

Q38887681-0BF932C1-2762-44A8-AB4E-28DC725E7C53

Q38887681-11F6F325-0FF9-41DA-BCDD-F67778E361C9

Q38887681-220D89A9-DDA9-4FF4-97DE-F0663C737513

Q38887681-2C233356-4188-4F94-AAB0-B18061384194

Q38887681-3BE412E6-A544-48EA-AFB7-6E8602BF8CF9

Q38887681-48F38A8F-6A79-449B-B53E-89C9EE6670CD

Q38887681-496613FC-9E6F-4928-B225-0B3066F11CE2

Q38887681-53C3CF12-F2BB-4AE7-8068-BF027460A6AF

P304

Q38887681-536E5CD5-3DF5-4FA6-BAF1-3E527A516B0A

P31

Q38887681-C440759A-F626-4B2B-B7B0-76DDA724C46F

P356

Q38887681-25CACF9F-00E7-427B-A755-31E3A098F36A

P407

Q38887681-017033E9-0EF7-426B-A847-6C0BDF2714BC

P433

Q38887681-3ED63C69-5855-4AE3-A873-68901B06D776

P478

Q38887681-7AF6E831-F466-4EAB-A8DC-DEB2308C62B7

P50

Q38887681-E6B90F39-41BB-40A9-A1E5-76503C3C43F1

P577

Q38887681-6A504CE7-C171-4A87-ADB1-3A78FE94BFAB

P698

Q38887681-EF2F70FB-5AE8-465D-BB8B-20D40FB96588

P932

Q38887681-560A4638-9C41-4DE6-AA27-741AFA76033C

P356

0008-5472.CAN-14-3167

P1433

Cancer Research

P1476

Acquired Resistance to the Mut ...... gnaling in Preclinical Models.

@en

P2093

Aleksandra A Markovets

http://www.w3.org/2001/XMLSchema#string

Ambar Ahmed

http://www.w3.org/2001/XMLSchema#string

Brian Dougherty

http://www.w3.org/2001/XMLSchema#string

Catherine A Eberlein

http://www.w3.org/2001/XMLSchema#string

Catherine B Meador

http://www.w3.org/2001/XMLSchema#string

Claire H Barnes

http://www.w3.org/2001/XMLSchema#string

Daniel Stetson

http://www.w3.org/2001/XMLSchema#string

Darren A E Cross

http://www.w3.org/2001/XMLSchema#string

Eiki Ichihara

http://www.w3.org/2001/XMLSchema#string

Elizabeth L Christey O'Brien

http://www.w3.org/2001/XMLSchema#string

P2860

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

P304

2489-2500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-14-3167

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25870145

http://www.w3.org/2001/XMLSchema#string

P932

4605607

http://www.w3.org/2001/XMLSchema#string